Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation

Abstract Background Novel circulating biomarkers may help in understanding the underlying mechanisms of atrial fibrillation (AF), a challenge for AF management and prevention of cardiovascular (CV) events. Whether glycosylation affects the prognostic value of N-terminal pro-B type natriuretic peptid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lidia Staszewsky, Jennifer M. T. A. Meessen, Deborah Novelli, Ursula-Henrike Wienhues-Thelen, Marcello Disertori, Aldo P. Maggioni, Serge Masson, Gianni Tognoni, Maria Grazia Franzosi, Donata Lucci, Roberto Latini
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Atrial fibrillation, biomarkers Brain natriuretic peptides Recurrence Cardiovascular hospitalization Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/15ba99606609469697a5b64268aac08d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:15ba99606609469697a5b64268aac08d
record_format	dspace
spelling	oai:doaj.org-article:15ba99606609469697a5b64268aac08d2021-11-21T12:04:14ZTotal NT-proBNP, a novel biomarker related to recurrent atrial fibrillation10.1186/s12872-021-02358-y1471-2261https://doaj.org/article/15ba99606609469697a5b64268aac08d2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12872-021-02358-yhttps://doaj.org/toc/1471-2261Abstract Background Novel circulating biomarkers may help in understanding the underlying mechanisms of atrial fibrillation (AF), a challenge for AF management and prevention of cardiovascular (CV) events. Whether glycosylation affects the prognostic value of N-terminal pro-B type natriuretic peptide (NT-proBNP) in AF is still unknown. Objectives To test how deglycosylated total NT-proBNP, NT-proBNP and a panel of biomarkers are associated with: (1) recurrent AF, (2) first hospitalization for CV reasons. Methods A total of 382 patients of the GISSI-AF trial in sinus rhythm with a history of AF, echocardiographic variables, total NT-proBNP, NT-proBNP and nine additional biomarkers [Total N-terminal pro-B type natriuretic peptide (Total NT proBNP), N-terminal pro-B type natriuretic peptide (NTproBNP), Angiopoietin 2 (Ang2), Bone morphogenic protein-10 (BMP10), Dickkopf-related protein-3 (DKK3), Endothelial cell specific molecule-1 (ESM1), Fatty acid-binding protein 3 (FABP3), Fibroblast growth factor 23 (FGF23), Growth differentiation factor-15 (GDF15), Insulin-like growth factor-binding protein-7 (IGFBP7) and Myosin binding protein C3 (MYPBC3)]. were assayed at baseline, 6 and 12 months under blind conditions in a laboratory at Roche Diagnostics, Penzberg, Germany. The associations between circulating biomarkers and AF at the 6- and 12-month visits, and their predictive value, were assessed in multivariable models with logistic regression analysis and Cox proportional hazards regression analysis. Biomarkers associations were modelled for 1SD increase in their level. Results Over a median follow-up of 365 days, 203/382 patients (53.1%) had at least one recurrence of AF and 16.3% were hospitalized for CV reasons. Total NT-proBNP, NT-proBNP, Ang2 and BMP10 showed the strongest associations with ongoing AF. Natriuretic peptides also predicted recurrent AF (total NT-proBNP: HR:1.19[1.04–1.36], p = 0.026; NT-proBNP: HR:1.19[1.06–1.35], p = 0.016; Ang2: HR:1.07[0.95–1.20], p = 0.283; BMP10: HR:1.09[0.96–1.25], p = 0.249) and CV hospitalization (total NT-proBNP: HR:1.57[1.29–1.90], p < 0.001 1.63], p = 0.097). Conclusions The association of total NT-proBNP with the risk of AF first recurrence was similar to that of NT-proBNP, suggesting no influence of glycosylation. Analogous results were obtained for the risk of first hospitalization for CV reasons. Natriuretic peptides, Ang2 and BMP10 were associated with ongoing AF. Findings from the last two biomarkers point to a pathogenic role of cardiac extracellular matrix and cardiomyocyte growth in the myocardium of the right atrium and ventricle.Lidia StaszewskyJennifer M. T. A. MeessenDeborah NovelliUrsula-Henrike Wienhues-ThelenMarcello DisertoriAldo P. MaggioniSerge MassonGianni TognoniMaria Grazia FranzosiDonata LucciRoberto LatiniBMCarticleAtrial fibrillation, biomarkersBrain natriuretic peptidesRecurrenceCardiovascular hospitalizationDiseases of the circulatory (Cardiovascular) systemRC666-701ENBMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Atrial fibrillation, biomarkers Brain natriuretic peptides Recurrence Cardiovascular hospitalization Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Atrial fibrillation, biomarkers Brain natriuretic peptides Recurrence Cardiovascular hospitalization Diseases of the circulatory (Cardiovascular) system RC666-701 Lidia Staszewsky Jennifer M. T. A. Meessen Deborah Novelli Ursula-Henrike Wienhues-Thelen Marcello Disertori Aldo P. Maggioni Serge Masson Gianni Tognoni Maria Grazia Franzosi Donata Lucci Roberto Latini Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
description	Abstract Background Novel circulating biomarkers may help in understanding the underlying mechanisms of atrial fibrillation (AF), a challenge for AF management and prevention of cardiovascular (CV) events. Whether glycosylation affects the prognostic value of N-terminal pro-B type natriuretic peptide (NT-proBNP) in AF is still unknown. Objectives To test how deglycosylated total NT-proBNP, NT-proBNP and a panel of biomarkers are associated with: (1) recurrent AF, (2) first hospitalization for CV reasons. Methods A total of 382 patients of the GISSI-AF trial in sinus rhythm with a history of AF, echocardiographic variables, total NT-proBNP, NT-proBNP and nine additional biomarkers [Total N-terminal pro-B type natriuretic peptide (Total NT proBNP), N-terminal pro-B type natriuretic peptide (NTproBNP), Angiopoietin 2 (Ang2), Bone morphogenic protein-10 (BMP10), Dickkopf-related protein-3 (DKK3), Endothelial cell specific molecule-1 (ESM1), Fatty acid-binding protein 3 (FABP3), Fibroblast growth factor 23 (FGF23), Growth differentiation factor-15 (GDF15), Insulin-like growth factor-binding protein-7 (IGFBP7) and Myosin binding protein C3 (MYPBC3)]. were assayed at baseline, 6 and 12 months under blind conditions in a laboratory at Roche Diagnostics, Penzberg, Germany. The associations between circulating biomarkers and AF at the 6- and 12-month visits, and their predictive value, were assessed in multivariable models with logistic regression analysis and Cox proportional hazards regression analysis. Biomarkers associations were modelled for 1SD increase in their level. Results Over a median follow-up of 365 days, 203/382 patients (53.1%) had at least one recurrence of AF and 16.3% were hospitalized for CV reasons. Total NT-proBNP, NT-proBNP, Ang2 and BMP10 showed the strongest associations with ongoing AF. Natriuretic peptides also predicted recurrent AF (total NT-proBNP: HR:1.19[1.04–1.36], p = 0.026; NT-proBNP: HR:1.19[1.06–1.35], p = 0.016; Ang2: HR:1.07[0.95–1.20], p = 0.283; BMP10: HR:1.09[0.96–1.25], p = 0.249) and CV hospitalization (total NT-proBNP: HR:1.57[1.29–1.90], p < 0.001 1.63], p = 0.097). Conclusions The association of total NT-proBNP with the risk of AF first recurrence was similar to that of NT-proBNP, suggesting no influence of glycosylation. Analogous results were obtained for the risk of first hospitalization for CV reasons. Natriuretic peptides, Ang2 and BMP10 were associated with ongoing AF. Findings from the last two biomarkers point to a pathogenic role of cardiac extracellular matrix and cardiomyocyte growth in the myocardium of the right atrium and ventricle.
format	article
author	Lidia Staszewsky Jennifer M. T. A. Meessen Deborah Novelli Ursula-Henrike Wienhues-Thelen Marcello Disertori Aldo P. Maggioni Serge Masson Gianni Tognoni Maria Grazia Franzosi Donata Lucci Roberto Latini
author_facet	Lidia Staszewsky Jennifer M. T. A. Meessen Deborah Novelli Ursula-Henrike Wienhues-Thelen Marcello Disertori Aldo P. Maggioni Serge Masson Gianni Tognoni Maria Grazia Franzosi Donata Lucci Roberto Latini
author_sort	Lidia Staszewsky
title	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_short	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_full	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_fullStr	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_full_unstemmed	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_sort	total nt-probnp, a novel biomarker related to recurrent atrial fibrillation
publisher	BMC
publishDate	2021
url	https://doaj.org/article/15ba99606609469697a5b64268aac08d
work_keys_str_mv	AT lidiastaszewsky totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT jennifermtameessen totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT deborahnovelli totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT ursulahenrikewienhuesthelen totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT marcellodisertori totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT aldopmaggioni totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT sergemasson totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT giannitognoni totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT mariagraziafranzosi totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT donatalucci totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT robertolatini totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
_version_	1718419229034676224

Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation

Ejemplares similares